Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Equity Average: 2019-2021

Historic Equity Average for Black Diamond Therapeutics (BDTX) over the last 3 years, with Sep 2021 value amounting to $235.0 million.

  • Black Diamond Therapeutics' Equity Average fell 29.90% to $235.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was $235.0 million, marking a year-over-year decrease of 29.90%. This contributed to the annual value of $130.3 million for FY2020, which is 515.64% up from last year.
  • Latest data reveals that Black Diamond Therapeutics reported Equity Average of $235.0 million as of Q3 2021, which was down 11.62% from $265.9 million recorded in Q2 2021.
  • In the past 5 years, Black Diamond Therapeutics' Equity Average registered a high of $349.2 million during Q2 2020, and its lowest value of -$43.5 million during Q4 2019.
  • In the last 3 years, Black Diamond Therapeutics' Equity Average had a median value of $235.0 million in 2021 and averaged $166.3 million.
  • As far as peak fluctuations go, Black Diamond Therapeutics' Equity Average soared by 1,478.77% in 2020, and later decreased by 29.90% in 2021.
  • Over the past 3 years, Black Diamond Therapeutics' Equity Average (Quarterly) stood at -$43.5 million in 2019, then surged by 830.43% to $317.6 million in 2020, then dropped by 29.90% to $235.0 million in 2021.
  • Its last three reported values are $235.0 million in Q3 2021, $265.9 million for Q2 2021, and $294.3 million during Q1 2021.